3-(4,4-二甲基-4,5-二氢-1,3-氧唑-2-基)吡啶 | 68981-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(4,4-二甲基-4,5-二氢-1,3-氧唑-2-基)吡啶
• 中文别名: 4,5-二羟基-4,4-二甲基-2-(3-吡啶)噁唑
• 英文名称: 3-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)pyridine
• 英文别名: 4,4-dimethyl-2-(pyridin-3-yl)-2-oxazoline；4,4-dimethyl-2-(pyridin-3-yl)-4,5-dihydrooxazole；3-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-pyridine；4,4-Dimethyl-2-(3-pyridyl)-oxazoline；4,5-Dihydro-4,4-dimethyl-2-(3-pyridyl)oxazole；4,4-dimethyl-2-pyridin-3-yl-5H-1,3-oxazole
• CAS: 68981-86-2
• 化学式: C₁₀H₁₂N₂O
• mdl: MFCD01313220
• 分子量: 176.218
• InChiKey: XYABHURTMBEOGW-UHFFFAOYSA-N

物化性质

• 熔点：
  25-27℃
• 沸点：
  89-91 °C(Press: 0.65 Torr)
• 密度：
  1.12±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  储存条件：2-8°C，避光，惰性气体环境下保存。

SDS

Name:	3-(4 4-Dimethyl-4 5-dihydro-1 3-oxazol-2-yl)pyridine 97% Material Safety Data Sheet
Synonym:	4,5-Dihydro-4,4-dimethyl-2-(3-pyridyl)oxazol
CAS:	68981-86-2

Section 1 - Chemical Product MSDS Name:3-(4 4-Dimethyl-4 5-dihydro-1 3-oxazol-2-yl)pyridine 97% Material Safety Data Sheet
Synonym:4,5-Dihydro-4,4-dimethyl-2-(3-pyridyl)oxazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
68981-86-2	3-(4,4-Dimethyl-4,5-dihydro-1,3-oxazol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 68981-86-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12N2O
Molecular Weight: 176

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 68981-86-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(4,4-Dimethyl-4,5-dihydro-1,3-oxazol-2-yl)pyridine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 68981-86-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 68981-86-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 68981-86-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(4,4-二甲基-4,5-二氢-1,3-氧唑-2-基)吡啶 在 盐酸 作用下， 生成 1,1-diethyl-1H-furo[3,4-c]pyridin-3-one
  参考文献：
  名称：

  Meyers,A.I.; Gabel,R.A., Heterocycles, 1978, vol. 11, p. 133 - 138

  摘要：

  DOI：
• 作为产物：
  描述：

  4,4-二甲基-2-氧唑啉 在 四(三苯基膦)钯 正丁基锂 、 三甲基氯化锡 作用下， 以 乙醚 为溶剂， 反应 30.0h， 生成 3-(4,4-二甲基-4,5-二氢-1,3-氧唑-2-基)吡啶
  参考文献：
  名称：

  Masked multifunctionalization of aromatics by palladium-catalyzed halogen-oxazoline exchange

  摘要：

  DOI：

  10.1016/s0040-4039(00)85187-4

文献信息

• A simple synthesis of Δ2-oxazines, Δ2-oxazines, Δ2-thiazolines and 2-substituted benzoxazoles
  作者：Helmut Vorbrüggen、Konrad Krolikiewicz

  DOI：10.1016/0040-4020(93)80021-k

  日期：1993.1

  Carboxylic acids react readily at O°→+24°C with amino alcohols, amino mercaptans and o-aminophenols in the presence of triphenylphosphine- or tributylphosphine dichloride (generated from the reaction of the phosphines with hexachloroethane or CCl4) and triethylamine in acetonitrile to form the corresponding Δ2-oxazolines, Δ2-oxazines, Δ2-thiazolines and 2-substituted benzoxazoles in reaction step in

  羧酸在三苯基膦或三丁基膦二氯化物（由膦与六氯乙烷或CCl 4的反应生成）和三乙胺在乙腈中的存在下，于0°→+ 24°C易与氨基醇，氨基硫醇和邻氨基酚反应形成相应的Δ 2个-oxazolines，Δ 2个-oxazines，Δ 2 -thiazolines和在2-取代苯并恶唑在高达80％的产率反应步骤。
• Direct synthesis of 2-oxazolines from carboxylic acids using 2-chloro-4,6-dimethoxy-1,3,5-triazine under mild conditions
  作者：B.P Bandgar、S.S Pandit

  DOI：10.1016/s0040-4039(03)00251-x

  日期：2003.3

  2-Acyloxy-4,6-dimethoxy-1,3,5-triazines obtained from carboxylic acids and 2-chloro-4,6-dimethoxy-1,3,5-triazine were subsequently treated with 2-amino-2-methyl-1-propanol to afford the corresponding 2-oxazolines in excellent yield at room temperature.

  随后将由羧酸获得的2-酰氧基-4,6-二甲氧基-1,3,5-三嗪和2-氯-4,6-二甲氧基-1,3,5-三嗪用2-氨基-2-甲基处理-1-丙醇在室温下以优异的收率得到相应的2-恶唑啉。
• The direct synthesis of 2-Oxazolines from carboxylic esters using lanthanide chloride as catalyst
  作者：Peiwen Zhou、Jason E. Blubaum、Christopher T. Burns、Nicholas R. Natale

  DOI：10.1016/s0040-4039(97)01641-9

  日期：1997.10

  Using catalytic amounts of lanthanide III (Ln = La, Sm) chlorides and amino alkoxides as reagents, an one-pot direct synthesis for 2-oxazolines, in good yield, from carboxylic esters has been developed.

  使用催化量的镧系元素III（Ln = La，Sm）氯化物和氨基醇盐作为试剂，已经开发了从羧酸酯一锅直接合成高收率的2-恶唑啉的方法。
• 1,2,3-Triazole and tetrazole substituted piperidine or
  申请人：H. Lundbeck A/S

  公开号：US04866077A1

  公开（公告）日：1989-09-12

  The present invention relates to novel compounds of the following formula, where the dotted line designates an optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,2,4- or 1,3,4-oxadiazole; R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy; R.sup.2 and R.sup.3 are the same or different, each representing hydrogen, lower alkyl, cycloalkyl (3-6 C-atoms), lower alkenyl, lower alkadienyl, lower alkynyl, optionally substituted with hydroxy, halogen or phenyl, in which the phenyl group may be substituted with halogen, trifluoromethyl, lower alkyl, hydroxy or lower alkoxy; R.sup.2 and R.sup.3 may further, respectively, be selected from trifluoromethyl or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy or lower acyloxy, or R.sup.2 and R.sup.3 may, respectively, be a group OR.sup.7 or SR.sup.7 wherein R.sup.7 is defined as R.sup.2 or R.sup.3, and if "het" includes 2 or more carbon atoms, R.sup.4 and R.sup.5 are the same or different, and each is defined as R.sup.2 or R.sup.3, and if "het" includes only one carbon atom, there is only one substituent, R.sup.4, on the heterocyclic ring, and R.sup.4 is defined as R.sup.2 or R.sup.3, as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula I, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式的新化合物，其中虚线表示可选键：##STR1##其中“het”表示一个五元杂环，可能包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，但“het”不能表示1,2,4-或1,3,4-噁二唑；R.sup.1选择自氢、较低的烷基，可选地取代为苯基，苯基可能被卤素、较低的烷基或较低的烷氧基取代，或者是一个基团R.sup.6--CO--NH--CH.sub.2--或R.sup.6--O--CO--，其中R.sup.6是较低的烷基、支链或直链，或者是可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基的苯基；R.sup.2和R.sup.3相同或不同，各自代表氢、较低的烷基、环烷基（3-6个碳原子）、较低的烯基、较低的烷二烯基、较低的炔基，可选地取代为羟基、卤素或苯基，其中苯基可能被卤素、三氟甲基、较低的烷基、羟基或较低的烷氧基取代；R.sup.2和R.sup.3还可以分别选择三氟甲基或可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基的苯基，或者R.sup.2和R.sup.3可以分别是一个基团OR.sup.7或SR.sup.7，其中R.sup.7定义为R.sup.2或R.sup.3，如果“het”包括2个或更多个碳原子，则R.sup.4和R.sup.5相同或不同，各自定义为R.sup.2或R.sup.3，如果“het”只包括一个碳原子，则在杂环上只有一个取代基R.sup.4，R.sup.4定义为R.sup.2或R.sup.3，以及其单独的立体异构体和药学上可接受的酸盐。此外，本发明还涉及制备式I化合物的方法，新的中间体，含有相同化合物的药物组合物，以及通过给予式I化合物的非毒性有效量来治疗由乙酰胆碱（AcCh）或肌碱系统功能障碍引起的疾病的方法。
• A Novel and Chemoselective Synthesis of 2-Aryloxazolines and Bis-oxazolines Catalyzed by Bi(III) Salts
  作者：Iraj Mohammadpoor-Baltork、Ahmad Reza Khosropour、Seyedeh Fatemeh Hojati

  DOI：10.1055/s-2005-918951

  日期：——

  Different arylnitriles react with β-aminoalcohols in the presence of catalytic amounts of Bi(III) salts such as Bi(TFA)3, Bi(OTf)3 and BiOClO4·xH2O producing the corresponding 2-aryl­oxazolines in high yields. Selective synthesis of mono- and bis-oxazolines from dicyanobenzenes and selective conversion of arylnitriles to their 2-oxazolines in the presence of alkylnitriles can be considered as noteworthy advantages of this method.

  不同的芳腈在催化量的Bi(III)盐（如Bi(TFA)3、Bi(OTf)3和BiOClO4·xH2O）存在下与β-氨醇反应，生成相应的2-芳基氧杂环丁烯，并且产率高。该方法的显著优势包括从二氰基苯选择性合成单个和双氧杂环丁烯，以及在烷基腈存在的情况下选择性将芳腈转化为其2-氧杂环丁烯。